Mind Medicine (MindMed) Inc
NASDAQ:MNMD

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Watchlist
Price: 7.56 USD 6.63% Market Closed
Market Cap: 554.4m USD
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mind Medicine (MindMed) Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Total Equity
$262.2m
CAGR 3-Years
16%
CAGR 5-Years
150%
CAGR 10-Years
91%
Bausch Health Companies Inc
TSX:BHC
Total Equity
-$1.2B
CAGR 3-Years
-79%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Total Equity
CA$1.2B
CAGR 3-Years
66%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Total Equity
$1.1B
CAGR 3-Years
-13%
CAGR 5-Years
3%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Total Equity
CA$773.9m
CAGR 3-Years
-4%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Total Equity
$1.1B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
554.4m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
3.7 USD
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Total Equity?
Total Equity
262.2m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Total Equity amounts to 262.2m USD.

What is Mind Medicine (MindMed) Inc's Total Equity growth rate?
Total Equity CAGR 10Y
91%

Over the last year, the Total Equity growth was 173%. The average annual Total Equity growth rates for Mind Medicine (MindMed) Inc have been 16% over the past three years , 150% over the past five years , and 91% over the past ten years .

Back to Top